title: Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma.
abstract: Systemic sclerosis (SSc) is a connective tissue disorder with an unknown etiology. There are currently no effective therapies for SSc. (In this study, working with a bleomycin(BLM)-induced scleroderma model mice, we performed two transfections of human hepatocyte growth factor (HGF) cDNA into the skeletal muscle and showed that this treatment not only helped to prevent the dermal sclerosis simultaneously injected BLM but also improved the symptoms of dermal sclerosis induced by BLM 4 weeks previously.) RT-PCR, ELISA and an immunohistochemical analysis revealed that both mRNA and protein of human HGF as well as murine HGF were enhanced in the skin, lung, muscle and the serum after two transfections of human HGF cDNA. These analyses also revealed that this treatment significantly reduced both the expression of the TGF-beta1 mRNA and the production of TGF-beta1 on macrophage-like cells that infiltrated the dermis and the fibroblastic cells in BLM-induced scleroderma. Furthermore, HGF-gene transfection both prevented and ameliorated the symptoms of not only dermal sclerosis but also of lung fibrosis induced by a subcutaneous BLM injection. These results indicated that gene therapy by the transfection of the human HGF cDNA may thus be a useful therapy for SSc and lung fibrosis involved with SSc.
authors.affiliation: Department of Dermatology and Immunodermatology, Tokyo Medical and Dental University, Graduate School, Tokyo, Japan.
authors.forename: M-H
authors.initials: MH
authors.lastname: Wu
authors.forename: H
authors.initials: H
authors.lastname: Yokozeki
authors.forename: S
authors.initials: S
authors.lastname: Takagawa
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: T
authors.initials: T
authors.lastname: Satoh
authors.forename: Y
authors.initials: Y
authors.lastname: Kaneda
authors.forename: I
authors.initials: I
authors.lastname: Katayama
authors.forename: K
authors.initials: K
authors.lastname: Nishioka
mesh_terms: D000818:Animals; D000963:Antimetabolites; D001761:Bleomycin; D005260:Female; D005355:Fibrosis; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics; D017228:Hepatocyte Growth Factor / Q000235:genetics*; D006801:Humans; D007273:Injections, Intramuscular; D008081:Liposomes; D008168:Lung / Q000473:pathology; D051379:Mice; D008809:Mice, Inbred C3H; D023421:Models, Animal; D012333:RNA, Messenger / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012594:Scleroderma, Localized / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D012595:Scleroderma, Systemic / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D029082:Sendai virus / Q000235:genetics; D014162:Transfection / Q000379:methods*; D016212:Transforming Growth Factor beta / Q000235:genetics* / Q000378:metabolism
chemical_list: D000963:Antimetabolites; D008081:Liposomes; D012333:RNA, Messenger; D016212:Transforming Growth Factor beta; D001761:Bleomycin; D017228:Hepatocyte Growth Factor